New antibody combo aims to tackle Hard-to-Treat multiple myeloma
Disease control
Completed
This trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC